New CKM guideline urges team-based care, yet UH data show major therapy gaps; CINEMA model boosts outcomes amid cost, trust, and handoff hurdles.
|Articles|March 1, 1999
The American Journal of Managed Care
- March 1999
- Volume 5
- Issue 3
Incorporating Clinical Outcomes and Economic Consequences into Drug Formulary Decisions: A Practical Approach
Advertisement
Articles in this issue
over 27 years ago
Economic Impact of Delaying or Preventing AIDS in Persons with HIVover 27 years ago
Erectile Dysfunction: The Primary Care Practitioner's Viewover 27 years ago
Drug-Nutrient InteractionsAdvertisement
Related to this article
Obesity care surges with GLP-1 demand, but fragmented ownership, prior authorizations, and coverage rules stall treatment—pharmacists step in.
Roundtables reveal HFpEF/HFmrEF care lags despite rising cases; learn new SGLT2/MRA strategies, screening, and scalable team pathways.
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves First Treatment for Sanfilippo Syndrome Type A
2
Real-World Data: FACT vs Non-FACT CAR T Outcomes Compared
3
No Blood Biomarker Is Ready to Pick Psoriasis Therapy
4
Oral GLP-1s, Medicare Bridge Reshape Obesity Care: Holly Lofton, MD
5